Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.
Quick Facts
What This Study Found
The Tα1 group had a 90-day liver transplantation-free survival rate of 75.0% compared to 53.4% in the SMT group.
Key Numbers
How They Did This
This was an open-label, randomized controlled trial involving 120 patients with HBV-related acute-on-chronic liver failure.
Why This Research Matters
These findings suggest that Tα1 could be a valuable treatment option for improving outcomes in patients with severe liver failure due to hepatitis B. Reducing infection rates is crucial for enhancing patient survival.
What This Study Doesn't Tell Us
The study was open-label and may have biases; further research is needed to confirm long-term effects and benefits in diverse populations.
Trust & Context
- Original Title:
- Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.
- Published In:
- Hepatology international, 16(4), 775-788 (2022)
- Authors:
- Chen, Jun-Feng, Chen, Shu-Ru, Lei, Zi-Ying, Cao, Hui-Juan, Zhang, Shao-Quan, Weng, Wei-Zhen, Xiong, Jing, Lin, Deng-Na, Zhang, Jing, Zheng, Yu-Bao, Gao, Zhi-Liang, Lin, Bing-Liang
- Database ID:
- RPEP-06042
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06042APA
Chen, Jun-Feng; Chen, Shu-Ru; Lei, Zi-Ying; Cao, Hui-Juan; Zhang, Shao-Quan; Weng, Wei-Zhen; Xiong, Jing; Lin, Deng-Na; Zhang, Jing; Zheng, Yu-Bao; Gao, Zhi-Liang; Lin, Bing-Liang. (2022). Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.. Hepatology international, 16(4), 775-788. https://doi.org/10.1007/s12072-022-10335-6
MLA
Chen, Jun-Feng, et al. "Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial.." Hepatology international, 2022. https://doi.org/10.1007/s12072-022-10335-6
RethinkPeptides
RethinkPeptides Research Database. "Safety and efficacy of Thymosin α1 in the treatment of hepat..." RPEP-06042. Retrieved from https://rethinkpeptides.com/research/chen-2022-safety-and-efficacy-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.